SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001517022-24-000045
Filing Date
2024-04-25
Accepted
2024-04-25 17:17:51
Documents
22
Period of Report
2024-04-25

Document Format Files

Seq Description Document Type Size
1 DEF 14A akba-20240425.htm   iXBRL DEF 14A 1439575
6 akba-20240425_g1.jpg GRAPHIC 20264
7 akba-20240425_g2.jpg GRAPHIC 5885
8 akba-20240425_g3.jpg GRAPHIC 83710
9 akba-20240425_g4.jpg GRAPHIC 34910
10 akba-20240425_g5.jpg GRAPHIC 35553
11 akba-20240425_g6.jpg GRAPHIC 150602
12 akba-20240425_g7.jpg GRAPHIC 126733
13 akba-20240425_g8.jpg GRAPHIC 128202
  Complete submission text file 0001517022-24-000045.txt   4011831

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT akba-20240425.xsd EX-101.SCH 4870
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT akba-20240425_def.xml EX-101.DEF 2436
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT akba-20240425_lab.xml EX-101.LAB 9700
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT akba-20240425_pre.xml EX-101.PRE 6112
25 EXTRACTED XBRL INSTANCE DOCUMENT akba-20240425_htm.xml XML 355762
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36352 | Film No.: 24877511
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)